title: [Analysis of adverse events following 2009 influenza A (H1N1) vaccinoprophylaxis in Beijing].
abstract: OBJECTIVE
  To evaluate the safety of 2009 influenza A (H1N1) vaccine based on mass immunization initiative in Beijing.
  
  
  METHODS
  There were 2 113 280 people were vaccinated during September to December 2009. The information of adverse events following immunization (AEFI) was collected through surveillance system, and descriptive methodology was used for data analysis.
  
  
  RESULTS
  A Total of 612 AEFI cases were reported, among which there were 321 vaccine reaction cases following immunization, 203 coincidental illness cases, 82 psychogenic reaction cases, and 6 pending cases. The rates of rare reactions and common reactions associated with vaccination were respectively 5.54/100 000 (117/2 113 280) and 9.65/100 000 (204/2 113 280). The rate of serious rare reaction was 0.19/100 000 (4/2 113 280). The rates of vaccine reactions in urban, suburb and county were 16.87/100 000 (36/213 519), 17.81/100 000 (187/1 049 817) and 11.53/100 000 (98/849 944), respectively. The rates of rare reaction and common reaction in different age groups were between 3.65/100 000 (6/164 604) to 8.99/100 000 (27/300 176), and between 0.61/100 000 (1/164 604) to 22.06/100 000 (85/385 275). The 117 rear vaccine reaction cases were mainly allergic reaction (107 cases), and the 204 common vaccine reaction cases were mainly fever (176 cases). There were 91.90% (295/321) vaccine reactions occurred within 24 hours of administration, and all cases had improved consequence.
  
  
  CONCLUSIONS
  The mostly symptoms of AEFI cases during the period of 2009 influenza A (H1N1) vaccinoprophylaxis were anaphylaxis and fever. The types of adverse reactions and the level of serious events are consistent with the anticipation. There were no rear or new events occurred.
authors.affiliation: Department of Immunization and Prevention, Beijing Center for Disease Prevention and Control, Beijing, China. lmiao168@hotmail.com
authors.forename: Liang
authors.initials: L
authors.lastname: Miao
authors.forename: Li
authors.initials: L
authors.lastname: Lu
authors.forename: Jiang
authors.initials: J
authors.lastname: Wu
authors.forename: Luo-dan
authors.initials: LD
authors.lastname: Suo
authors.forename: Dong-lei
authors.initials: DL
authors.lastname: Liu
authors.forename: Mei-ping
authors.initials: MP
authors.lastname: Sun
authors.forename: Xing-huo
authors.initials: XH
authors.lastname: Pang
authors.forename: Ying
authors.initials: Y
authors.lastname: Deng
authors.forename: Xiao-li
authors.initials: XL
authors.lastname: Wang
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002648:Child; D002675:Child, Preschool; D002681:China / Q000453:epidemiology; D005260:Female; D005334:Fever / Q000139:chemically induced; D006801:Humans; D006967:Hypersensitivity / Q000453:epidemiology; D007114:Immunization; D053118:Influenza A Virus, H1N1 Subtype; D007252:Influenza Vaccines / Q000009:adverse effects*; D007251:Influenza, Human / Q000453:epidemiology / Q000517:prevention & control*; D008297:Male; D032541:Mass Vaccination; D008875:Middle Aged; D011159:Population Surveillance; D055815:Young Adult
chemical_list: D007252:Influenza Vaccines